"text","uuid:ID","label","name","instanceType","description","id"
"To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","1b21327c-5471-4cfd-a5b7-ba150007099c","","OBJ1","Objective","Main objective","Objective_1"
"To document the safety profile of the xanomeline TTS.","6ee3393d-c47c-45f2-98d2-8ac36d968052","","OBJ2","Objective","Safety","Objective_2"
"To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","5837aa1d-61db-4774-93ad-4c1dc762c847","","OBJ3","Objective","Behaviour","Objective_3"
"To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5).","d43b249e-e89c-49d6-93e6-32c6c620cf95","","OBJ4","Objective","","Objective_4"
"To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2).","3e04ef6f-6e48-4486-9a3d-1ffccbe7dadf","","OBJ5","Objective","","Objective_5"
"To assess the treatment response as a function of Apo E genotype.","c96a1b2f-464c-4358-9167-2834af5de5c5","","OBJ6","Objective","","Objective_6"
